trial

EXSCEL

Definition

Cardiovascular outcomes for once-weekly exenatide in 14,752 adults with type 2 diabetes (Holman et al., NEJM 2017) — and the primary outcome was NEUTRAL. Exenatide did not significantly reduce MACE, which is why “GLP-1s protect the heart” is a claim about specific molecules rather than the class.

EXSCEL trial deep-dive

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under trial

Where the evidence lives